About Yili Pharmaceutical Technology
Company footprint
Moments of glory
Core competition
Fluvastatin Sodium Extended Release Tablets
For patients with primary hypercholesterolemia and mixed dyslipidemia (Freclrickson lla and llb types) that are not fully controlled by diet.
Ondansetron Hydrochloride Injection
This product is used to control nausea and vomiting caused by cancer chemotherapy and radiation therapy; It is also suitable for the prevention and treatment of postoperative nausea and vomiting.
Compound Amino Acids (19) and Alanyl Glutamine Injection
To provide parenteral nutrition and supplement amino acids for adult patients when enteral nutrition is not feasible, insufficient or contraindicated. This product contains alanyl glutamine and is suitable for adult trauma patients.
Levetiracetam Concentrated Solution for injection
Neurosurgery, neurology, oncology and other departments with clinical needs for prevention of craniocerebral diseases, early perioperative seizures, control of acute recurrent seizures, termination of epileptic status, etc
-
Company profile
-
Company size
-
Corporate culture
-
Medical research
-
Corporate image
Multiple and simultaneous
Have the courage to create breakthroughs and apply new technologies
Company profile
Chongqing Yili Pharmaceutical Technology Co., Ltd. was established in 2019, located in Nanan District, Chongqing, is a MAH certified company with drug production license (Class B). Covering Beijing Yili Technology Co., LTD., Chongqing Fangzhou Pharmaceutical Co., LTD., the company focuses on the research and development of chemical drugs and biological products, and expands the field of pharmaceutical sales. It has developed into a comprehensive pharmaceutical enterprise integrating pharmaceutical research and development, production and distribution. After several years of business exploration, the company has carried out research and development layout of innovative drugs and high-tech barriers generic drugs in the core medical field through independent development, external introduction, project cooperation and other ways. At present, the company has a national Class A new drug, the first imitation drug. At present, the company holds a total of 5 approvals, 8 products to be approved, 6 varieties in research, and 11 varieties sold by other manufacturers.
moreCompany size
The company has a strong sales team, the existing sales staff of 100 people. In all regions of the country, there are special personnel responsible for following up the bidding, sales and after-sales services. Now it has gradually established a sales network covering 90% of the administrative regions of the country, the business covers nearly 70 cities, and the products are sold to 31 provinces (municipalities directly under the Central Government) and autonomous regions. Since its establishment in 2019, the company has maintained a strong momentum of growing annual sales revenue. The company has a professional team, can quickly achieve the target products in various provinces and bid, and quickly into the hospital sales. In 2022, under the background of domestic collection and epidemic control, the company achieved sales revenue of more than 1 billion yuan, an increase of nearly 20%, highlighting the company's marketing strength.
moreCorporate culture
The company has always adhered to the "integrity" business philosophy. Relying on technological innovation, a standardized unified service system has been developed to meet the needs of personalized market development.
Enterprise spirit: truth-seeking, unity, dedication, innovation;
Enterprise purpose: pay attention to quality, integrity-based;
Enterprise philosophy: Scientific management, integrity management;
Enterprise service: Customer first, heart service
Medical research
The company's research and development targets focus on solid slow-controlled preparations, injections, hormones and other varieties with technical thresholds. Covering oncology, anesthesiology, cardiovascular surgery, neurosurgery, gynecology, pediatrics and other departments. Gradually extend to clinical general medicine. In addition, according to the characteristics of its strong sales ability, the company focuses on research and development in the fields of specialty drugs, cardiovascular drugs, endocrine system drugs and special dosage forms for children. Strive to accumulate products in these areas and form a domestic competitive enterprise in sales.
moreCorporate image
The company has strong academic support and promotion ability, and through the current advantageous varieties to establish their own expert resources, and the main committee of the provinces can effectively interact, and with a number of domestic medical associations have in-depth cooperation. The professional team of academic promotion and efficient sales team are combined to provide good products and services for many terminal hospitals and customers throughout the country, and strive to create a rigorous and professional corporate image in the industry.
more
Levetiracetam concentrated solution for injection was approved for marketing by the State Drug Admin
2023-06-16Levetiracetam concentrated solution for injection (5ml:500mg) of our company was developed with Keppra® as the reference preparation according to the technical requirements of consistency evaluation of quality and efficacy.
Compound amino acid (19) propyl glutamine dipeptide injection was approved for drug marketing by the
2023-06-16This product has a wide range of clinical use (can be used in the general practice), and the indication is to provide parenteral nutrition and supplement amino acids for adult patients when enteral nutrition is not feasible, insufficient or contraindicated. This product contains alanyl glutamine and is suitable for adult trauma patients.
Ondansetron hydrochloride injection is pleased to select the seventh batch of national centralized p
2023-06-16Ondansetron is a selective 5-HT3 receptor antagonist, which can effectively suppress or relieve nausea and vomiting caused by cytotoxic chemotherapy drugs and radiotherapy. Ondansetron has a rapid and powerful inhibitory effect on vomiting caused by some strong emetic chemotherapy drugs (such as cisplatin, cyclophosphamide, etc.).
Fluvastatin sodium sustained-release tablets received marketing approval from the State Drug Adminis
2023-06-16Fluvastatin is A hydroxymethylglutaryl-Coenzyme A (HMG-CoA) reductase suppressant for patients with primary hypercholesterolemia and mixed dyslipidemia (FredricksonⅡa and Ⅱb types) that is not fully controlled by diet.
网站首页
产品中心
添加微信
电话咨询
WeChat number：